{
    "clinical_study": {
        "@rank": "136012", 
        "acronym": "I-TEAM", 
        "arm_group": [
            {
                "arm_group_label": "Lutein-enriched-egg beverage", 
                "arm_group_type": "Active Comparator", 
                "description": "Powder in sachets is provided and dissolved to prepare Lutein-enriched-egg beverage"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Powder in sachet to prepare beverage"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the I-TEAM project is to assess whether there is a change in visual function\n      and status of the retina after a year of intervention in subjects with early signs of\n      Age-related Macular Degeneration."
        }, 
        "brief_title": "Intervention Trial in Early Age-related Macular Degeneration", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Age-related Macular Degeneration (AMD)", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Early AMD (AREDS category 2)\n\n               -  many small drusen, or\n\n               -  a few intermediate-sized (63-124 micrometres in diameter) drusen, or\n\n               -  macular pigmentary changes\n\n        OR\n\n          -  Intermediate AMD (AREDS category 3)\n\n               -  extensive intermediate sized (63-124 micrometres in diameter) drusen, or\n\n               -  at least one large (>125 micrometers in diameter) drusen or\n\n               -  geographic atrophy not involving the foveal centre\n\n          -  men and women age \u226550 years\n\n          -  BMI 18-35 kg/m2\n\n          -  Vision \u2265 20/40 for Snellen visual acuity\n\n          -  lutein intake of < 2 mg/day (including supplements)\n\n          -  DHA intake of < 150 mg/day (including supplements)\n\n          -  must be able to give written informed consent\n\n          -  have normal hematologic parameters\n\n          -  normal values of plasma albumin\n\n          -  normal values for liver and kidney function\n\n          -  no use of carotenoid, fish oil, or n3 fatty acid supplements (within 1 month of study\n             start)\n\n        Exclusion Criteria:\n\n          -  ocular media opacity (severe cataract)\n\n          -  history of active small bowel disease or resection\n\n          -  atrophic gastritis\n\n          -  history of hyperlipidemia or screening values as follows (LDL > 5.33mmol/L or\n             205mg/dL; triglycerides > 4.52mmol/L or >400 mg/dL)\n\n          -  hypertension (>150/90 mm Hg)\n\n          -  diabetes mellitus (if also accompanied by signs of diabetic retinopathy)\n\n          -  alcohol intake of >2 drinks/day or 14 drinks/week\n\n          -  pancreatic disease\n\n          -  dementia or Alzheimer's disease\n\n          -  anemia, and bleeding disorders\n\n          -  known allergy to egg or egg products\n\n          -  known allergy to milk or milk products\n\n          -  known allergy to cocoa or chocolate products\n\n          -  known allergy to fish or fish oils\n\n          -  lactose intolerance\n\n          -  pregnancy or lactation\n\n          -  diseases that interfere with fat absorption, e.g. colitis, celiac disease, Crohn's\n             disease, cystic fibrosis (as determined by screening interview)\n\n          -  medication or supplements that contain a significant level of carotenoids, including\n             an amount of lutein of more than 0.25 mg per day within 1 month of the study start\n\n          -  medications that interfere with fat absorption, e.g. bile sequestrants (as determined\n             by screening interview)\n\n          -  use of antipsychotic, anti manic, or dementia medications\n\n          -  smoking or use of nicotine patches or gum (within the past 6 months)\n\n          -  subjects having extremely high dietary intakes of carotenoids\n\n          -  stroke, head injury with loss of consciousness or seizures\n\n          -  for US and UK center: Non English speaking"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01694680", 
            "org_study_id": "NWT-02/Human 4"
        }, 
        "intervention": {
            "arm_group_label": "Lutein-enriched-egg beverage", 
            "intervention_name": "Lutein-enriched-egg beverage", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "AMD", 
            "Lutein", 
            "Visual function", 
            "Early signs of AMD", 
            "AREDS-category 2"
        ], 
        "lastchanged_date": "November 26, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "EJ Johnson, PhD", 
                    "phone": "617-556-3204"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "TUFTS University"
                }, 
                "investigator": {
                    "last_name": "E Reichel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "christian.brinkmann@ukb.uni.bonn.de", 
                    "last_name": "C. Brinkmann, PhD", 
                    "phone": "+49-1752490103"
                }, 
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany"
                    }, 
                    "name": "Universit\u00e4ts Augenklinik - Bonn"
                }, 
                "investigator": {
                    "last_name": "Prof F Holz, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ian.j.murray@manchester.ac.uk", 
                    "last_name": "I Murray, PhD", 
                    "phone": "+44-1613063886"
                }, 
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Manchester Royal Eye Hospital - Manchester"
                }, 
                "investigator": {
                    "last_name": "I Murray, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Intervention Study to Assess the Effect of Daily Consumption of a Lutein-enriched-egg Beverage on Maintenance of Visual Function in Subjects With Early Signs of Age-related Macular Degeneration", 
        "overall_official": {
            "affiliation": "Jean Mayer USDA Human Nutrition Research Center on Aging (HNRCA), Boston", 
            "last_name": "E J Johnson, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Europe: European Food Safety Authority (EFSA)", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Visual function", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01694680"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Levels of lutein and Zeaxanthin", 
            "measure": "Carotenoid levels", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Newtricious R&D BV", 
        "sponsors": {
            "collaborator": {
                "agency": "Sprim Italia", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Newtricious R&D BV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}